Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia
出版年份 2022 全文链接
标题
Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 31, Issue 12, Pages 1279-1290
出版商
Informa UK Limited
发表日期
2022-12-19
DOI
10.1080/13543784.2022.2158811
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials
- (2022) Heidi Taipale et al. JAMA Psychiatry
- Oral and long‐acting antipsychotics for relapse prevention in schizophrenia‐spectrum disorders: a network meta‐analysis of 92 randomized trials including 22,645 participants
- (2022) Giovanni Ostuzzi et al. World Psychiatry
- Towards Novel Treatments for Schizophrenia: Molecular and Behavioural Signatures of the Psychotropic Agent SEP-363856
- (2021) Veronica Begni et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention
- (2021) Felipe V. Gomes et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effect of TAAR1/5-HT1A agonist SEP-363856 on REM sleep in humans
- (2021) Seth C. Hopkins et al. Translational Psychiatry
- Binding of SEP-363856 within TAAR1 and the 5HT1A receptor: implications for the design of novel antipsychotic drugs
- (2021) Pramod C. Nair et al. MOLECULAR PSYCHIATRY
- The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: Network meta-analyses of randomized controlled trials
- (2021) Daniel Prates Baldez et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia
- (2021) Gerald R. Galluppi et al. CPT-Pharmacometrics & Systems Pharmacology
- Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS
- (2021) Seth C. Hopkins et al. CLINICAL DRUG INVESTIGATION
- Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions
- (2021) Joshua T. Kantrowitz CNS DRUGS
- Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats
- (2021) Colleen Synan et al. DRUG AND ALCOHOL DEPENDENCE
- Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies
- (2021) Nina Dedic et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics
- (2021) Maria C. Lobo et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study
- (2021) Christoph U. Correll et al. npj Schizophrenia
- Dopamine and glutamate in schizophrenia: biology, symptoms and treatment
- (2020) Robert A. McCutcheon et al. World Psychiatry
- Precision and personalized assessment, diagnosis and treatment in psychiatry
- (2020) Konstantinos N. Fountoulakis et al. CNS SPECTRUMS
- Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine
- (2020) Michelle Kokkinou et al. MOLECULAR PSYCHIATRY
- A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
- (2020) Kenneth S. Koblan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey
- (2020) Rajiv Tandon et al. Annals of General Psychiatry
- Trace Amine-Associated Receptor 1 (TAAR1): A new drug target for psychiatry?
- (2020) Seetal Dodd et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Characterization of specific and distinct patient types in clinical trials of acute schizophrenia using an uncorrelated PANSS score matrix transform (UPSM)
- (2020) Seth C. Hopkins et al. PSYCHIATRY RESEARCH
- SEP-363856, A NOVEL PSYCHOTROPIC AGENT WITH A UNIQUE, NON-D2 RECEPTOR MECHANISM OF ACTION
- (2019) Nina Dedic et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis
- (2019) Maximilian Huhn et al. LANCET
- Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology
- (2019) Stephen J. Kaar et al. NEUROPHARMACOLOGY
- Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities
- (2019) Amanda Krogmann et al. CNS SPECTRUMS
- Actions of Trace Amines in the Brain-Gut-Microbiome Axis via Trace Amine-Associated Receptor-1 (TAAR1)
- (2019) Katlynn Bugda Gwilt et al. CELLULAR AND MOLECULAR NEUROBIOLOGY
- Trace Amines and Their Receptors
- (2018) Raul R. Gainetdinov et al. PHARMACOLOGICAL REVIEWS
- Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges
- (2017) Mark D. Berry et al. PHARMACOLOGY & THERAPEUTICS
- Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia
- (2017) Seth C Hopkins et al. SCHIZOPHRENIA BULLETIN
- Impaired Glucose Homeostasis in First-Episode Schizophrenia
- (2017) Toby Pillinger et al. JAMA Psychiatry
- Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review
- (2017) Marco Solmi et al. Therapeutics and Clinical Risk Management
- Role of TAAR1 within the Subregions of the Mesocorticolimbic Dopaminergic System in Cocaine-Seeking Behavior
- (2016) Jian-Feng Liu et al. JOURNAL OF NEUROSCIENCE
- Schizophrenia
- (2015) René S. Kahn et al. Nature Reviews Disease Primers
- Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia
- (2014) Maren Carbon et al. CNS SPECTRUMS
- Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials
- (2014) Paolo Fusar-Poli et al. SCHIZOPHRENIA BULLETIN
- A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia
- (2012) Marco DiBonaventura et al. BMC Psychiatry
- Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis
- (2012) Stefan Leucht et al. LANCET
- Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009
- (2012) Juan A. Gallego et al. SCHIZOPHRENIA RESEARCH
- Functional Interaction between Trace Amine-Associated Receptor 1 and Dopamine D2 Receptor
- (2011) S. Espinoza et al. MOLECULAR PHARMACOLOGY
- Antipsychotic polypharmacy: A survey study of prescriber attitudes, knowledge and behavior
- (2011) Christoph U. Correll et al. SCHIZOPHRENIA RESEARCH
- From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics
- (2010) C.U. Correll EUROPEAN PSYCHIATRY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started